Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Jul 22, 2026

Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide

Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting them to expert neurologist options nationwide. CHICAGO, July 16, 2026 /PRNewswire/ -- Synapticure, a leading virtual care company dedicated to improving access and outcomes for patients and caregivers living with neurodegenerative diseases, today announced the launch of a virtual ataxia care program.

PRNewsWire • Jul 16, 2026

Biogen Appoints Michael J. Parini as Chief Legal Officer

CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of Biogen's Executive Committee and report to Christopher A. Viehbacher, President and Chief Executive Officer. In this role, Mr. Parini will have responsibility for oversight of Biogen's global legal and compliance functions.

GlobeNewsWire • Jul 15, 2026

Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data

BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.

Zacks Investment Research • Jul 15, 2026

Biogen's Alzheimer's drug lowers toxic protein, but results were mixed

The lowest dose of Biogen's anti-tau Alzheimer's drug diranersen, which missed its primary goal in a midstage ​trial, reduced cognitive decline in five of six Alzheimer's assessment tools and significantly cut levels of the toxic protein in the brain, researchers ‌reported on Tuesday.

Reuters • Jul 14, 2026

Can Biogen Score Another Win In Alzheimer's Disease?

Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.

Investors Business Daily • Jul 14, 2026

Biogen Backs Alzheimer's Tau Drug for Phase 3 Despite Trial Miss

Biogen NASDAQ: BIIB said data from its Phase 2 CELIA study of diranersen in early Alzheimer's disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary endpoint of demonstrating a predefined dose-response pattern.

MarketBeat • Jul 14, 2026

Why Is Biogen Stock Falling Tuesday?

Biogen Inc. (NASDAQ:BIIB) on Tuesday said it will advance investigational Alzheimer's therapy diranersen into Phase 3 testing after new Phase 2 data showed the tau-targeting treatment slowed clinical decline while producing significant biomarker reductions.

Benzinga • Jul 14, 2026

Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 Transcript

Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 Transcript

Seeking Alpha • Jul 14, 2026

Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease

CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease. The data, presented at the Alzheimer's Association International Conference (AAIC) 2026, expand upon previously reported topline results and demonstrate a combination of meaningful clinical efficacy and robust biomarker effects, providing Phase 2 proof of concept for diranersen's tau-directed mechanism of action. Based on the growing and consistent body of evidence from the Phase 1b and Phase 2 studies, Biogen plans to advance diranersen into confirmatory Phase 3 development.1

GlobeNewsWire • Jul 14, 2026